AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BCAL DIAGNOSTICS LTD

0.090

-0.004-4.26%

Volume:33.30K

Turnover:3K

Market Cap:33.13M

PE:-4.49

High:0.090

Open:0.090

Low:0.090

Close:0.094

52wk High:0.155

52wk Low:0.052

Shares:368.07M

Float Shares:202.44M

Volume Ratio:0.10

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.020

EPS(LYR):-0.020

ROE:-273.29%

ROA:-50.29%

PB:-40.09

PE(LYR):-4.50

Loading ...

Overview Company News Filings

Barclays Initiates Coverage on Becton, Dickinson and Company With Underweight Rating, $165 Price Target

MT Newswires Live

Beckton Dickinson to Invest $3 Billion in Local US Medical Product Manufacturing

MT Newswires Live

Becton Dickinson (BDX) Names Art Hu Digital Chief As AI Push Comes Into Focus

Simply Wall St.

Argus Research Adjusts Becton, Dickinson and Company Price Target to $210 From $180, Maintains Buy Rating

MT Newswires Live

BCAL Diagnostics Launching Cancer Detection Test in Australia; Shares Rise 4%

MT Newswires Live

BCAL Diagnostics Ltd - Introduces Avantect Multi-Cancer Early Detection Test

THOMSON REUTERS

BCAL Diagnostics - Comments Attributed in Article Refer to Views of Some Fund Managers Who Have Been Advocating for a Three-Way Merger

THOMSON REUTERS

BCAL Diagnostics Ltd - Comments were not Made on Behalf of Bcal

THOMSON REUTERS

BCAL Diagnostics Ltd - Clarification of Bcal's Position in Relation to Genetic Signatures

THOMSON REUTERS

BCAL Diagnostics - Confirms not Made or Received Any Proposal and not in Discussions with Gss or Map for Merger or Other Combination

THOMSON REUTERS

BCAL Diagnostics Ltd-Bcal Seeks Board Change at Genetic Signatures

THOMSON REUTERS

BCAL Diagnostics - Requests Removal of Michael Aicher and Appointment of Forrester and Melki to Gss Board

THOMSON REUTERS

Genetic Signatures - Requested BCAL Diagnostics to Clarify Details of Its Shareholdings and Associates in Gss

THOMSON REUTERS

BCAL Diagnostics Ltd-Meet the CEO FY 2026 Results Webinar 3 Sept 2026 at 1Pm

THOMSON REUTERS

Becton Dickinson (BDX) Hits STANCE Trial Milestone, Is The Stock Fully Valued?

Simply Wall St.

Becton Dickinson Reaches 50% Enrollment in Breast Surgery Trial

MT Newswires Live

Did Stronger Sales and Quality Shuffle Just Shift Becton Dickinson's (BDX) Investment Narrative?

Simply Wall St.

Becton Dickinson Names Gary Sorsher as Chief Quality Officer

MT Newswires Live

Becton, Dickinson's Consistent Mid-Single-Digit Organic Growth is 12-18 Months Away, RBC Says

MT Newswires Live

Becton, Dickinson Completes Enrollment in Trial for Phasix Mesh

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BDX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","market":"AU","secType":"STK","nameCN":"BCAL DIAGNOSTICS LTD","latestPrice":0.09,"timestamp":1791436320000,"preClose":0.094,"halted":0,"volume":33298,"delay":0,"changeRate":-0.04255319148936174,"nameEN":"BCAL DIAGNOSTICS LTD","floatShares":202437334,"shares":368067640,"eps":-0.020055,"marketStatus":"Closed","change":-0.004,"latestTime":"10-08 16:12:00 AEDT","open":0.09,"high":0.09,"low":0.09,"amount":2997,"amplitude":0,"askPrice":0.092,"askSize":44000,"bidPrice":0.09,"bidSize":22702,"shortable":3,"etf":0,"ttmEps":-0.020055,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791500400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.094,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":0.098981,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BDX.AU","preClose":0.093,"auctionPrice":0.094,"auctionVolume":118,"auction":3,"marketStatus":"盘后竞价","timestamp":1791349200691}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","floatShares":202437334,"roa":"-50.29%","roe":"-273.29%","lyrEps":-0.02,"volumeRatio":0.098981,"shares":368067640,"dividePrice":0,"high":0.09,"amplitude":0,"preClose":0.094,"low":0.09,"week52Low":0.052,"pbRate":"-40.09","psRate":"14.08","week52High":0.155,"institutionHeld":0,"latestPrice":0.09,"committee":-0.319301,"eps":-0.020055,"divideRate":0,"volume":33298,"delay":0,"ttmEps":-0.020055,"open":0.09,"prevYearClose":0.105,"prevWeekClose":0.087,"prevMonthClose":0.09,"prevQuarterClose":0.09,"fiveDayClose":0.09,"twentyDayClose":0.076,"sixtyDayClose":0.076},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BDX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"BDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788393600000,"name":null,"time":"","dateTimestamp":1788357600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BDX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BDX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673900940","title":"Barclays Initiates Coverage on Becton, Dickinson and Company With Underweight Rating, $165 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673900940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673900940?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:07","pubTimestamp":1791374862,"startTime":"0","endTime":"0","summary":"Becton Dickinson and Company (BDX) has an average rating of overweight and mean price target of $193, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resear","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0289739343.SGD","LU0266013472.USD","BDX.AU","LU0130103400.USD","LU0130518102.USD","IE00BFXG1179.USD","IHI","LU1059921491.USD","LU0068578508.USD","LU0511384066.AUD","BDX","LU1150488218.USD","LU1894683264.USD","LU1571399168.USD","LU0878866978.SGD","LU1854103824.USD","LU1201861165.SGD","LU1489326972.SGD","BK4585","BK4588","BK7067","LU0072461881.USD","LU0006061336.USD","LU0985320562.USD","LU0648000940.SGD","LU1150488135.SGD","BK4082","LU1894683348.USD","LU0477156797.USD","LU0433182093.SGD","LU0289961442.SGD","LU1854104046.USD","LU0162691827.USD","BK4504","LU0985489474.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673034276","title":"Beckton Dickinson to Invest $3 Billion in Local US Medical Product Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673034276","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673034276?lang=en_us&edition=fundamental","pubTime":"2026-10-06 15:39","pubTimestamp":1791272343,"startTime":"0","endTime":"0","summary":"Beckton Dickinson  agreed to invest $3 billion to onshore manufacturing of essential medical products, US President Donald Trump said Monday.The plan includes over $1 billion to expand production in Nebraska for items such as needles made with American steel, Trump said on Truth Social.The decision follows planned medical device tariffs scheduled to take effect by the end of the year, he added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFXG1179.USD","LU1894683264.USD","LU1150488135.SGD","IHI","BK4588","LU0985489474.SGD","LU1489326972.SGD","LU1150488218.USD","BK4504","LU0130103400.USD","LU0162691827.USD","LU0072461881.USD","LU1059921491.USD","LU1201861165.SGD","LU1894683348.USD","LU0289961442.SGD","LU0130518102.USD","LU0433182093.SGD","BK7067","LU0289739343.SGD","LU1854104046.USD","LU0878866978.SGD","LU0477156797.USD","LU1854103824.USD","LU0266013472.USD","LU0985320562.USD","BK4082","BDX.AU","LU0006061336.USD","LU0068578508.USD","LU1571399168.USD","LU0648000940.SGD","BK4585","LU0511384066.AUD","BDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672207087","title":"Becton Dickinson (BDX) Names Art Hu Digital Chief As AI Push Comes Into Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2672207087","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672207087?lang=en_us&edition=fundamental","pubTime":"2026-10-04 18:19","pubTimestamp":1791109189,"startTime":"0","endTime":"0","summary":"Becton Dickinson (NYSE:BDX) appointed Arthur (Art) Hu as Executive Vice President and Chief Information and Digital Officer.\nHu joins BD after senior technology and digital leadership roles at Lenovo and consulting firm McKinsey & Company.\nHis remit covers information technology, digital platforms, and AI adoption across BD's global medical technology operations.\nThe appointment of Art Hu as Chief Information and Digital Officer is only one piece of what matters for BD as an investment. Take...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/103678-card/1788996209058","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/103678-card/1788996209058"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-names-art-hu-digital-chief-as-ai-push-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-names-art-hu-digital-chief-as-ai-push-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BDX","ARTY","LU0266013472.USD","LU1201861165.SGD","LU1854103824.USD","LU0511384066.AUD","LU0006061336.USD","LU0130518102.USD","LU0130103400.USD","LU0433182093.SGD","LU0648000940.SGD","BK4504","BDX.AU","LU1894683264.USD","VTHR","QTOC","LU1059921491.USD","LU0068578508.USD","LU0162691827.USD","AGIX","BK7067","LU1571399168.USD","LU1150488135.SGD","LU0072461881.USD","LU0477156797.USD","LU0985320562.USD","CHAT","BK4585","LU1489326972.SGD","BK4588","BK4082","LU1894683348.USD","LU0985489474.SGD","IE00BFXG1179.USD","AIPO","LU1150488218.USD","LU0289961442.SGD","LU0878866978.SGD","LU1854104046.USD","LU0289739343.SGD","IHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672123227","title":"Argus Research Adjusts Becton, Dickinson and Company Price Target to $210 From $180, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2672123227","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672123227?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:00","pubTimestamp":1790946038,"startTime":"0","endTime":"0","summary":"Becton Dickinson and Company (BDX) has an average rating of overweight and mean price target of $193, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0477156797.USD","LU0985489474.SGD","LU0266013472.USD","LU1894683348.USD","BK4585","BK7067","LU0985320562.USD","LU0130103400.USD","LU1489326972.SGD","IE00BFXG1179.USD","LU1854103824.USD","LU0006061336.USD","LU0648000940.SGD","LU1571399168.USD","LU0130518102.USD","LU0162691827.USD","LU0289961442.SGD","IHI","LU0289739343.SGD","LU1150488135.SGD","LU1894683264.USD","LU1059921491.USD","LU1150488218.USD","BK4504","LU0068578508.USD","LU0511384066.AUD","BK4588","BK4082","LU1201861165.SGD","BDX","LU0072461881.USD","LU1854104046.USD","LU0433182093.SGD","BDX.AU","LU0878866978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669179767","title":"BCAL Diagnostics Launching Cancer Detection Test in Australia; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669179767","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669179767?lang=en_us&edition=fundamental","pubTime":"2026-09-23 10:22","pubTimestamp":1790130174,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics  is launching its Avantect multi-cancer early detection test in Australia, with an initial rollout in Sydney and Melbourne ahead of a broader national release, according to a Wednesday filing with the Australian bourse.The blood test looks for cancer-associated signals across eight cancer types, including lung, pancreatic, liver, ovarian, gastric, esophageal, breast, and colorectal cancer, to provide a likely organ-of-origin signal, per the filing.In a case-controlled validation study, the test showed overall sensitivity of 56.2% and specificity of 98.4% across all the analyzed cancers, the company said.Its shares rose 4% in recent Wednesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IIGF.AU","IOZ.AU","VAP.AU","OZR.AU","BK7067","GEAR.AU","OZF.AU","IMLC.AU","ZYAU.AU","SLF.AU","XAO.AU","EIGA.AU","DACE.AU","QRE.AU","XKO.AU","BEAR.AU","QFN.AU","BBOZ.AU","STW.AU","IISV.AU","XJO.AU","GIVE.AU","E200.AU","VAS.AU","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669755481","title":"BCAL Diagnostics Ltd - Introduces Avantect Multi-Cancer Early Detection Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2669755481","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669755481?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:44","pubTimestamp":1790124288,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0OS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554179","title":"BCAL Diagnostics - Comments Attributed in Article Refer to Views of Some Fund Managers Who Have Been Advocating for a Three-Way Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554179?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:20","pubTimestamp":1789010413,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4511BP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554171","title":"BCAL Diagnostics Ltd - Comments were not Made on Behalf of Bcal","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554171?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:20","pubTimestamp":1789010413,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4511BP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666541745","title":"BCAL Diagnostics Ltd - Clarification of Bcal's Position in Relation to Genetic Signatures","url":"https://stock-news.laohu8.com/highlight/detail?id=2666541745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666541745?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:20","pubTimestamp":1789010413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4511BP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666177554","title":"BCAL Diagnostics - Confirms not Made or Received Any Proposal and not in Discussions with Gss or Map for Merger or Other Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2666177554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666177554?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:20","pubTimestamp":1789010413,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4511BP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664527823","title":"BCAL Diagnostics Ltd-Bcal Seeks Board Change at Genetic Signatures","url":"https://stock-news.laohu8.com/highlight/detail?id=2664527823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664527823?lang=en_us&edition=fundamental","pubTime":"2026-09-03 10:40","pubTimestamp":1788403215,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUEV0GFX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664236888","title":"BCAL Diagnostics - Requests Removal of Michael Aicher and Appointment of Forrester and Melki to Gss Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2664236888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664236888?lang=en_us&edition=fundamental","pubTime":"2026-09-03 10:40","pubTimestamp":1788403215,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUEV0GFX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7048","BK7067","BDX.AU","GSS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664842699","title":"Genetic Signatures - Requested BCAL Diagnostics to Clarify Details of Its Shareholdings and Associates in Gss","url":"https://stock-news.laohu8.com/highlight/detail?id=2664842699","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664842699?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:38","pubTimestamp":1788392299,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U16O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7048","BK7067","BDX.AU","GSS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663825024","title":"BCAL Diagnostics Ltd-Meet the CEO FY 2026 Results Webinar 3 Sept 2026 at 1Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2663825024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663825024?lang=en_us&edition=fundamental","pubTime":"2026-08-31 12:30","pubTimestamp":1788150646,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUE9N79Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019352","title":"Becton Dickinson (BDX) Hits STANCE Trial Milestone, Is The Stock Fully Valued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019352","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019352?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:30","pubTimestamp":1787959830,"startTime":"0","endTime":"0","summary":"Becton Dickinson (BDX) stock is back in focus after the company reported that its STANCE clinical trial of GalaFLEX LITE Scaffold in breast revision surgery hit a first enrollment milestone, triggering a planned interim analysis.\nAgainst this backdrop, Becton Dickinson shares trade at US$189.52, with the stock posting a 30 day share price return of 12.54% and a 90 day share price return of 28.82%. The 1 year total shareholder return of 28.03% contrasts with a weaker 3 year record and points...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-hits-stance-trial-milestone-is-the-stoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-hits-stance-trial-milestone-is-the-stoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","LU0266013472.USD","LU0878866978.SGD","LU1489326972.SGD","LU1150488135.SGD","LU0162691827.USD","LU0985320562.USD","LU1150488218.USD","BDX","LU1059921491.USD","IE00BFXG1179.USD","BK4588","BK7067","LU0130103400.USD","LU1201861165.SGD","LU1894683264.USD","LU0433182093.SGD","LU1894683348.USD","LU0072461881.USD","LU0477156797.USD","LU0289739343.SGD","LU0289961442.SGD","LU0511384066.AUD","LU0006061336.USD","BK4082","LU1571399168.USD","LU0130518102.USD","LU1854104046.USD","LU0985489474.SGD","LU1854103824.USD","LU0648000940.SGD","LU0068578508.USD","BDX.AU","BK4504","IHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662670497","title":"Becton Dickinson Reaches 50% Enrollment in Breast Surgery Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662670497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662670497?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:43","pubTimestamp":1787831011,"startTime":"0","endTime":"0","summary":"Becton, Dickinson and Co.  said Thursday that its clinical study evaluating GalaFLEX LITE Scaffold in breast revision surgery for capsular contracture has treated 274 patients across 33 active US states.The total number shows over 50% of planned enrollment and has triggered the first planned interim analysis, the medical technology company said.The trial evaluates the bioabsorbable device for treating capsular contracture, a complication where scar tissue hardens around implants, the company said.Shares of the company were down less than 1% in recent Thursday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","LU0433182093.SGD","LU0130103400.USD","LU1894683264.USD","LU1489326972.SGD","LU0289961442.SGD","LU0162691827.USD","LU0648000940.SGD","LU0068578508.USD","LU0878866978.SGD","LU1150488218.USD","LU0985489474.SGD","LU0985320562.USD","LU0006061336.USD","LU1854103824.USD","LU0072461881.USD","LU0477156797.USD","LU1150488135.SGD","LU1854104046.USD","LU1894683348.USD","BDX","LU1201861165.SGD","BK4504","IHI","LU1571399168.USD","BK4585","BK7067","LU1059921491.USD","LU0130518102.USD","BDX.AU","LU0511384066.AUD","IE00BFXG1179.USD","LU0289739343.SGD","BK4588","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660949476","title":"Did Stronger Sales and Quality Shuffle Just Shift Becton Dickinson's (BDX) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660949476","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660949476?lang=en_us&edition=fundamental","pubTime":"2026-08-20 05:33","pubTimestamp":1787175181,"startTime":"0","endTime":"0","summary":"Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results showing higher sales of US$4,983,000,000 compared with a year earlier, while net income for both the quarter and year-to-date periods was lower than the prior year.\nAlongside these mixed earnings, BD advanced its tissue regeneration pipeline by fully enrolling the PREVENT trial for Phasix Mesh and reshaped its quality leadership team with the upcoming appointment of Gary Sorsher as chief quality officer and the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/did-stronger-sales-and-quality-shuffle-just-shift-becton-dic","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/did-stronger-sales-and-quality-shuffle-just-shift-becton-dic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BDX.AU","BDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432145","title":"Becton Dickinson Names Gary Sorsher as Chief Quality Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432145","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432145?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:42","pubTimestamp":1786999370,"startTime":"0","endTime":"0","summary":"Becton Dickinson  has named Gary Sorsher as chief quality officer, effective Sept. 8, the company said late Monday.Sorsher was most recently chief quality officer at Edwards Lifesciences , the company said.Becton Dickinson also said that Jeffrey Silvestri, global head of quality, will retire in October.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1854104046.USD","IE00BFXG1179.USD","IHI","BDX.AU","LU0058720904.USD","LU0648000940.SGD","LU0068578508.USD","BK4504","IE00BYQQ9H92.USD","IE00BN0W2W23.USD","LU0289739343.SGD","LU1201861165.SGD","LU0130103400.USD","LU1854103824.USD","SG9999001176.SGD","LU0345774391.USD","BK4082","LU0289961442.SGD","LU0878866978.SGD","BMED","LU1571399168.USD","LU0006061336.USD","BK4567","IE00BN0W2V16.EUR","LU1489326972.SGD","SGXZ57979304.SGD","LU0072461881.USD","LU0289739699.SGD","LU0433182093.SGD","LU1150488135.SGD","LU0985489474.SGD","BDX","LU0477156797.USD","BK4588","IE00BFXG0V08.USD","LU1894683264.USD","LU0266013472.USD","EW","LU0985320562.USD","BK7067","LU0162691827.USD","AGNG","LU0130518102.USD","LU0823416689.USD","BK4585","LU0345774631.USD","LU1150488218.USD","IE00BN0W2T93.GBP","LU1894683348.USD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659166809","title":"Becton, Dickinson's Consistent Mid-Single-Digit Organic Growth is 12-18 Months Away, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659166809","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659166809?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:59","pubTimestamp":1786636784,"startTime":"0","endTime":"0","summary":"Becton, Dickinson  will take 12 to 18 months to have consistent mid-single-digit organic growth as headwinds are expected to persist through fiscal 2027, RBC Capital Markets said in a Thursday note.The company is aiming for a long-term profile of mid-single-digit revenue growth and high-single-digit EPS growth with dividends, RBC analysts said. For fiscal 2027, the management is taking a responsible stance, with revenue growth expected in the low-single digits and modest EPS leverage, according to the note.The analysts said the expected headwinds impacting the company are China, where sales are seen falling to about 3% of revenue in fiscal 2027; its vaccine business, which is down about 30% in the current year but seen stabilizing into the next year; and its Alaris infusion system.RBC is positive on the company's diversified portfolio, BD Excellence program productivity, and commercial momentum across its growth platforms.RBC reiterated the company's stock rating at sector-perform and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1854103824.USD","LU0289739343.SGD","BK4082","LU0006061336.USD","LU1894683348.USD","LU0648000940.SGD","LU1489326972.SGD","LU1854104046.USD","BK4585","LU0072461881.USD","BDX","BDX.AU","LU1150488135.SGD","LU1894683264.USD","IE00BFXG1179.USD","LU0433182093.SGD","LU0511384066.AUD","LU0985320562.USD","LU0266013472.USD","LU0878866978.SGD","LU0985489474.SGD","LU1150488218.USD","IHI","LU1201861165.SGD","BK4588","LU0130518102.USD","LU1059921491.USD","LU0477156797.USD","LU0068578508.USD","BK7067","BK4504","LU0289961442.SGD","LU0130103400.USD","LU0162691827.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974933","title":"Becton, Dickinson Completes Enrollment in Trial for Phasix Mesh","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974933","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974933?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:31","pubTimestamp":1786534268,"startTime":"0","endTime":"0","summary":"Becton, Dickinson  said Wednesday it completed enrollment in a trial evaluating Phasix Mesh for preventing incisional hernias.The company said the study enrolled 477 patients across 32 sites in the US and Europe and will evaluate the use of resorbable mesh to prevent incisional hernias.Patients will be followed through the trial's primary endpoint at 24 months, with longer-term follow-up planned for five years, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1150488218.USD","BK4082","LU0068578508.USD","LU0130518102.USD","LU0511384066.AUD","BK7067","BK4504","LU0477156797.USD","BK4585","LU0289961442.SGD","BK4588","LU1059921491.USD","LU1489326972.SGD","BDX","LU0985489474.SGD","LU1201861165.SGD","LU0266013472.USD","LU0433182093.SGD","LU0162691827.USD","IE00BFXG1179.USD","IHI","LU1894683348.USD","LU0878866978.SGD","LU0130103400.USD","LU0289739343.SGD","BDX.AU","LU0648000940.SGD","LU1854103824.USD","LU1854104046.USD","LU1894683264.USD","LU0072461881.USD","LU1150488135.SGD","LU0006061336.USD","LU1571399168.USD","LU0985320562.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}]}}